Fennec Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Fennec Pharmaceuticals

30/03/2023 24:26

* Fennec Pharmaceuticals Inc  FENC.OQ  reported a quarterly
adjusted loss of 26 cents​​ per share for the quarter ended in
December. The mean expectation of six analysts for the quarter
was for a loss of 26 cents per share.
    * Revenue was $1.54 million​; analysts expected $744.83
thousand. 
    * Fennec Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 26 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Fennec Pharmaceuticals Inc shares had fallen by 12.4% this
quarter.
    * The company reported a quarterly loss of $6.86 million.
    * Wall Street's median 12-month price target for Fennec
Pharmaceuticals Inc is $16.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 29 at 11:26 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.26          -0.26          Met
 Sep. 30 2022      -0.18          -0.31          Missed
 Jun. 30 2022      -0.14          -0.19          Missed
 Mar. 31 2022      -0.14          -0.14          Met